Mylan expands cancer drug recall on particle contamination worries

Companies are eyeing sterile injectable drugs for growth, but the formulas are notoriously tricky to manufacture. Mylan ($MYL) has found that out the hard way, and it's now expanding a recall of cancer drugs that it began in April because they may contain particulate. Some of the drugs were manufactured for Pfizer ($PFE). More from FiercePharmaManufacturing